Cue Biopharma, Inc. (CUE) Revenue History
Annual and quarterly revenue from 2015 to present
CUE Revenue Over Time (2015–2025)
CUE Revenue Growth History
5 of 7 years with positive growth- FY2015 revenue growth
- N/A
- FY2016 revenue growth
- N/A
- FY2017 revenue growth
- N/A
- FY2018 revenue growth
- N/A
- FY2019 revenue growth
- +202.7%
- FY2020 revenue growth
- -8.8%
- FY2021 revenue growth
- +373.7%
- FY2022 revenue growth
- -91.7%
- FY2023 revenue growth
- +341.0%
- FY2024 revenue growth
- +69.2%
- FY2025 revenue growth
- +195.7%
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $5.7M | +1250.6% |
| Q4 2025 | $21.9M | +1292.3% |
| Q3 2025 | $2.1M | -35.6% |
| Q2 2025 | $3.0M | +11.1% |
| Q1 2025 | $421K | -75.5% |
| Q4 2024 | $1.6M | -13.5% |
| Q3 2024 | $3.3M | +58.9% |
| Q2 2024 | $2.7M | +92.3% |
Multi-year avg. share of annual revenue by fiscal quarter
CUE Revenue Analysis (2015–2025)
Current Revenue & Growth
As of June 28, 2026, Cue Biopharma, Inc. (CUE) generated trailing twelve-month (TTM) revenue of $32.7 million, reflecting explosive growth of +1250.6% year-over-year. The most recent quarter (Q1 2026) recorded $5.7 million in revenue, down 74.1% sequentially.
Historical Growth Trajectory
CUE's 5-year compound annual growth rate (CAGR) stands at +54.2%, indicating outstanding long-term growth trajectory. The 3-year CAGR of +180.5% exceeds the 5-year average, indicating an acceleration in the most recent period. Cue Biopharma, Inc.'s highest annual revenue of $27.5 million was recorded in 2025, an all-time high.
Peer Comparison
Compared to Healthcare sector peers — including AGIO (+78.3% YoY), KYMR (-12.6% YoY), and RCUS (+67.4% YoY) — CUE has outperformed the peer group in revenue growth. Compare CUE vs AGIO →
CUE Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| CUECurrent | $33M | +1250.6% | +54.2% | -96.6% | |
 AGIO | $54M | +78.3% | - | -873.9% | |
 KYMR | $39M | -12.6% | +2.9% | -891.3% | |
 RCUS | $247M | +67.4% | +25.9% | -156.3% | |
 TGTX | $616M | +81.3% | +426.7% | 20.0% |
CUE Historical Revenue Data (2015–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $27.5M | +195.7% | $27.5M | 100.0% | $-26,521,000 | -96.6% |
| 2024 | $9.3M | +69.2% | $9.3M | 100.0% | $-41,500,000 | -446.9% |
| 2023 | $5.5M | +341.0% | $-32,607,000 | -593.9% | $-52,149,000 | -949.9% |
| 2022 | $1.2M | -91.7% | $1.2M | 100.0% | $-53,225,000 | -4275.1% |
| 2021 | $14.9M | +373.7% | $16.7M | 111.9% | $-43,712,073 | -292.6% |
| 2020 | $3.2M | -8.8% | $-30,391,379 | -963.5% | $-45,042,585 | -1428.0% |
| 2019 | $3.5M | +202.7% | $-24,029,154 | -694.8% | $-36,769,247 | -1063.2% |
| 2018 | $1.1M | - | $-27,401,447 | -2398.2% | $-38,696,658 | -3386.7% |
| 2017 | $0 | - | $-419,568 | - | $-23,233,870 | - |
| 2016 | $0 | - | $-202,085 | - | $-7,658,335 | - |
| 2015 | $0 | - | $-44,815 | - | $-1,928,730 | - |
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
11+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
CUE — Frequently Asked Questions
Quick answers to the most common questions about buying CUE stock.
Is CUE's revenue growth accelerating or slowing?
CUE revenue growth is accelerating. TTM revenue reached $33M, up +1250.6% year-over-year — ahead of the 5-year CAGR of +54.2%. This indicates the business is expanding faster than its historical baseline.
What is CUE's revenue history from 2015 to 2026?
Cue Biopharma, Inc. (CUE) revenue history spans 2015 to 2026. TTM revenue as of 2026 is $33M, growing at +1250.6% YoY. The 5-year CAGR is +54.2%. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is CUE's long-term revenue growth rate (CAGR)?
Cue Biopharma, Inc.'s 5-year revenue CAGR of +54.2% reflects the sustained nature of its business expansion. As of 2026, the current YoY growth rate of +1250.6% is above this long-term average. CAGR is the most reliable measure of sustained revenue momentum for CUE.
Why does CUE's quarterly revenue fluctuate?
CUE quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Cue Biopharma, Inc.'s revenue data from 2015 to 2026 shows full historical quarterly detail on this page.
How is CUE's revenue distributed by segment?
CUE reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does CUE's revenue compare to industry peers?
Cue Biopharma, Inc. (CUE) with TTM revenue of $33M and +1250.6% YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.